Reply to: "A role for non-selective beta-blockers in preventing liver decompensation in patients with hepatocellular carcinoma undergoing systemic therapy": Advancing clinical trial design and patient care in hepatocellular carcinoma.
사설/논평
0/5 보강
APA
Celsa C, Pinato DJ, Cabibbo G (2026). Reply to: "A role for non-selective beta-blockers in preventing liver decompensation in patients with hepatocellular carcinoma undergoing systemic therapy": Advancing clinical trial design and patient care in hepatocellular carcinoma.. Journal of hepatology, 84(2), e77-e79. https://doi.org/10.1016/j.jhep.2025.10.009
MLA
Celsa C, et al.. "Reply to: "A role for non-selective beta-blockers in preventing liver decompensation in patients with hepatocellular carcinoma undergoing systemic therapy": Advancing clinical trial design and patient care in hepatocellular carcinoma.." Journal of hepatology, vol. 84, no. 2, 2026, pp. e77-e79.
PMID
41110521 ↗
같은 제1저자의 인용 많은 논문 (4)
- Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study.
- PHENO-RAG: An artificial intelligence tool for guideline-informed management decisions in hepatocellular carcinoma.
- Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis.
- Risk of hepatic and extrahepatic outcomes associated with metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction and alcohol-associated steatotic liver disease: a systematic review and meta-analysis.